MediWound director buys 6,000 shares in open market
MediWound Ltd. director Nachum Shamir reported buying 6,000 ordinary shares in the open market.
Rhea-AI Filing Summary
MediWound Ltd. director Nachum Shamir reported buying 6,000 ordinary shares in the open market. The Form 4 shows two purchase transactions on June 3, 2026, involving 5,825 shares at $14.00 per share and 175 shares at $13.975 per share.
Following these purchases, Shamir directly holds 49,990 ordinary shares. He also has 1,200 ordinary shares underlying RSUs that were granted on March 4, 2026 and vest in full one year after the grant date. In addition, he holds several stock option grants and Series A warrants over ordinary shares with exercise prices between $11.8850 and $18.5400, and Series A warrants exercisable at $13.4750 per share through November 28, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,000 shares
Net Buy
9 txns
Insider
SHAMIR NACHUM
Role
Director
Bought
6,000 shs ($84K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares | 175 | $13.975 | $2K |
| Purchase | Ordinary Shares | 5,825 | $14.00 | $82K |
| holding | Series A Warrants | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Ordinary shares — 57,015 shares (Direct);
Series A Warrants — 16,336 contracts (Direct);
Stock Option (right to buy ordinary shares) — 72,141 contracts (Direct)
Footnotes (3)
- F1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
- F2. There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Key Figures
Shares purchased: 6,000 shares
Purchase prices: $14.00 and $13.975 per share
Direct ordinary share holdings: 49,990 shares
+4 more
7 metrics
Shares purchased
6,000 shares
Ordinary shares bought on June 3, 2026
Purchase prices
$14.00 and $13.975 per share
Open-market purchase transactions
Direct ordinary share holdings
49,990 shares
Held directly after reported purchases
RSUs underlying shares
1,200 shares
RSUs granted March 4, 2026; vest in one year
Largest option grant
28,571 underlying shares at $12.4950
Stock option expiring August 17, 2032
Series A Warrants
16,336 underlying shares at $13.4750
Warrants expiring November 28, 2026
Other option exercise prices
$11.8850–$18.5400 per share
Remaining stock option positions over ordinary shares
Key Terms
RSUs, open-market purchase, Stock Option (right to buy ordinary shares), Series A Warrants, +1 more
5 terms
RSUs financial
"shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Series A Warrants financial
"security_title: "Series A Warrants""
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MediWound (MDWD) director Nachum Shamir do in this Form 4?
Nachum Shamir reported open-market purchases of MediWound shares. On June 3, 2026, he bought 6,000 ordinary shares in two trades, according to the Form 4, increasing his direct ownership while also disclosing existing RSUs, stock options, and Series A warrants.
What RSUs are disclosed for MediWound (MDWD) director Nachum Shamir?
The filing lists 1,200 ordinary shares underlying RSUs. These RSUs were granted on March 4, 2026 and are scheduled to vest in full on the one-year anniversary of the grant date, with the row included for informational purposes and no separate transaction reported.
What stock options does the MediWound (MDWD) director hold according to this Form 4?
Shamir holds several stock option grants over ordinary shares. The derivative summary shows options with exercise prices ranging from $11.8850 to $18.5400 per share, expiring between 2032 and 2036, each tied to specific underlying ordinary share amounts.
What are the Series A Warrants disclosed for MediWound (MDWD) in this filing?
The Form 4 reports Series A Warrants held by the director. These warrants relate to 16,336 underlying ordinary shares, with an exercise price of $13.4750 per share and an expiration date of November 28, 2026, and are reported as directly owned derivative securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
